Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben-Horin

Showing results (321-330 of 362) with videos related to

Pageof 37
Sort By:
Journal of Clinical Medicine|April 13, 2023
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort StudyAhmad Albshesh, Lian Bannon, Tali Sharar Fischler, et al.
The American Journal of Gastroenterology|February 12, 2019
Individualized Dynamics in the Gut Microbiota Precede Crohn's Disease FlaresTzipi Braun, Ayelet Di Segni, Marina BenShoshan, et al.
Gastroenterology|March 7, 2021
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel DiseaseStefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, et al.
Journal of Gastroenterology and Hepatology|August 2, 2020
Impact of COVID-19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South ChinaYing-Fan Zhang, Yun Qiu, Jin-Shen He, et al.
Gut Microbes|December 15, 2025
Supplementation with endogenous healthy gut metabolites reverses the disruptions of in vitro and ex vivo epithelial functions induced by fecal content from IBD patientsHaya Abbas-Egbariya, Lubna Elwahidi, David Jessula Levy, et al.
The American Journal of Gastroenterology|June 6, 2018
Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC StudyBella Ungar, Tal Engel, Doron Yablecovitch, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 28, 2025
Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT StudyAhmad Albshesh, Piotr Kucha, Daniela Pugliese, et al.
United European Gastroenterology Journal|March 28, 2020
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli studyAriella Bar-Gil Shitrit, Ami Ben-Ya'acov, Matan Siterman, et al.
Journal of Crohn'S & Colitis|March 6, 2015
Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agentsKonstantinos Karmiris, Peter Bossuyt, Dario Sorrentino, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 10, 2022
Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled TrialShomron Ben-Horin, Ofir Har-Noy, Konstantinos H Katsanos, et al.
Pageof 37

Showing results (321-330 of 362) with videos related to

Sort By:
Pageof 37
Journal of Clinical Medicine|April 13, 2023
Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn's Disease: A Multi-Center Retrospective Cohort StudyAhmad Albshesh, Lian Bannon, Tali Sharar Fischler, et al.
The American Journal of Gastroenterology|February 12, 2019
Individualized Dynamics in the Gut Microbiota Precede Crohn's Disease FlaresTzipi Braun, Ayelet Di Segni, Marina BenShoshan, et al.
Gastroenterology|March 7, 2021
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel DiseaseStefan Schreiber, Shomron Ben-Horin, Jaroslaw Leszczyszyn, et al.
Journal of Gastroenterology and Hepatology|August 2, 2020
Impact of COVID-19 outbreak on the care of patients with inflammatory bowel disease: A comparison before and after the outbreak in South ChinaYing-Fan Zhang, Yun Qiu, Jin-Shen He, et al.
Gut Microbes|December 15, 2025
Supplementation with endogenous healthy gut metabolites reverses the disruptions of in vitro and ex vivo epithelial functions induced by fecal content from IBD patientsHaya Abbas-Egbariya, Lubna Elwahidi, David Jessula Levy, et al.
The American Journal of Gastroenterology|June 6, 2018
Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC StudyBella Ungar, Tal Engel, Doron Yablecovitch, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|October 28, 2025
Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT StudyAhmad Albshesh, Piotr Kucha, Daniela Pugliese, et al.
United European Gastroenterology Journal|March 28, 2020
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli studyAriella Bar-Gil Shitrit, Ami Ben-Ya'acov, Matan Siterman, et al.
Journal of Crohn'S & Colitis|March 6, 2015
Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agentsKonstantinos Karmiris, Peter Bossuyt, Dario Sorrentino, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 10, 2022
Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled TrialShomron Ben-Horin, Ofir Har-Noy, Konstantinos H Katsanos, et al.
Pageof 37